bit225 a novel inhibitor of hiv 1 release from hiv 1
play

BIT225, a Novel Inhibitor of HIV-1 Release from HIV-1 Reservoirs of - PDF document

Nov 06, 2022 •156 likes •302 views

BIT225, a Novel Inhibitor of HIV-1 Release from HIV-1 Reservoirs of the Myeloid Lineage John Wilkinson* 1 , Carolyn Luscombe 1 , Gary Ewart 1 , Stephen Kerr 2 , Nattaya Tanliang 3 , Winai Ratanasuwan 3 , Robert Murphy 4 , and Michelle Miller 1 1

Recommend

AGM 16 October 2009 Key Highlights for 2008/2009 Successful completion of Phase I/IIa

AGM 16 October 2009 Key Highlights for 2008/2009 Successful completion of Phase I/IIa

ASX:BIT AGM 16 October 2009 Key Highlights for 2008/2009 Successful completion of Phase I/IIa clinical trial (BIT225-003) of BIT225 in Hep C+ subjects Successful rights issue, raising $0.8 million in March 09 1 BIT225-003:

276 views • 14 slides
BI 201335, a NS3/4A Serine Protease Inhibitor, and BI 207127, a NNI NS5b Polymerase Inhibitor for

BI 201335, a NS3/4A Serine Protease Inhibitor, and BI 207127, a NNI NS5b Polymerase Inhibitor for

BI 201335, a NS3/4A Serine Protease Inhibitor, and BI 207127, a NNI NS5b Polymerase Inhibitor for treatment of chronic HCV infection Wulf Otto Bcher Boehringer Ingelheim Pharma, Biberach, Germany NS3/4A Protease Inhibitor BI 201335 Chemical

629 views • 15 slides
GP IIB/IIIA Inhibitor Use During GP IIB/IIIA Inhibitor Use During Endovascular Intervention

GP IIB/IIIA Inhibitor Use During GP IIB/IIIA Inhibitor Use During Endovascular Intervention

GP IIB/IIIA Inhibitor Use During GP IIB/IIIA Inhibitor Use During Endovascular Intervention Endovascular Intervention Jay S. Yadav M.D. Director, Vascular Intervention Dept of Cardiovascular Medicine The Cleveland Clinic Foundation Name: Jay

1.03k views • 44 slides
HPPD-inhibitor resistance stewardship: The perspective of the HRAC HPPD- inhibitor Working Group

HPPD-inhibitor resistance stewardship: The perspective of the HRAC HPPD- inhibitor Working Group

2014 WSSA Vancouver, British Columbia HPPD-inhibitor resistance stewardship: The perspective of the HRAC HPPD- inhibitor Working Group Gordon D. Vail 1 , Roland S. Beffa 2 , William L. Patzoldt 3 , Peter J. Porpiglia 4 and Walter E. Thomas 5

543 views • 16 slides
PhenX Measures: Inhibitors Barbara Konkle and Diane Nugent 4.18 Inhibitors Assays

PhenX Measures: Inhibitors Barbara Konkle and Diane Nugent 4.18 Inhibitors Assays

PhenX Measures: Inhibitors Barbara Konkle and Diane Nugent 4.18 Inhibitors Assays Existing Inhibitor State Evolving Inhibitor State Resolving or Persistent Inhibitor State Laboratory Measures of Inhibitor Impact Factor VIII

275 views • 12 slides
European Inhibitor Network World Haemophilia Day Strasbourg, 19 April 2017 What is the European

European Inhibitor Network World Haemophilia Day Strasbourg, 19 April 2017 What is the European

European Inhibitor Network World Haemophilia Day Strasbourg, 19 April 2017 What is the European Inhibitor Network? Idea was presented at workshop on the EHC conference in Belgrade 2015 Combat isolation of people with inhibitors (PWI)

526 views • 11 slides
efits of the I inhibitor ivabradine be f inhibitor ivabradine f Y artery d in patients with

efits of the I inhibitor ivabradine be f inhibitor ivabradine f Y artery d in patients with

S tudy assess I n G the morbidity-mortality S tudy assess I n G the morbidity-mortality N efits of the I be N efits of the I inhibitor ivabradine be f inhibitor ivabradine f Y artery d in patients with coronar Y artery disease isease in

695 views • 20 slides
Umbralisib, A Novel PI3 I3K and Casein Kin inase-1 In Inhibitor, , in in Chronic

Umbralisib, A Novel PI3 I3K and Casein Kin inase-1 In Inhibitor, , in in Chronic

Umbralisib, A Novel PI3 I3K and Casein Kin inase-1 In Inhibitor, , in in Chronic Lymphocytic Leukemia and Lymphoma Anthony R Mato, , MD MSCE Memorial Slo loan Kettering Cancer Center NEW DRUGS IN IN HEMATOLOGY BOLOGNA 2018

438 views • 31 slides
What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor

What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor

What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) Marie Louise S. Christiansen MD, PhD Affiliation: Danish Medicines Agency Declaration of Interests Employment: No interests

557 views • 19 slides
PIT Release Date Functionality 15-May CAB Release

PIT Release Date Functionality 15-May CAB Release

PIT Release Date Functionality 15-May CAB Release Enumeration alignment 24-May Batching Payroll Submission SOAP Bug fixes 19-Jun Agent access Returns Reconciliation

623 views • 26 slides
PIT Release

PIT Release

PIT Release Date Functionality 15-May CAB Release Enumeration alignment 24-May Batching Payroll Submission SOAP Bug fixes 19-June

506 views • 21 slides
AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue

AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue

AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue Specific Abnormalities of Galactosemia in a GALT Deficient Rat Model of Disease Riccardo Perfetti, MD, PhD Chief Medical Officer, Applied Therapeutics

312 views • 13 slides
Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with

Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with

Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Activity Against all HCV Genotypes Richard Colonno, Ningwu Huang, Margaret Bencsik, Eric Peng, Anja Huq, Qi Huang, Min Zhong and Leping Li Presidio

783 views • 15 slides
BLU-782 A highly selective ALK2 inhibitor, designed specifically to target the cause of

BLU-782 A highly selective ALK2 inhibitor, designed specifically to target the cause of

BLU-782 A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva Andrew Garner, Ph.D. ASBMR ANNUAL MEETING SEPTEMBER 30, 2018 Disclosures I am an employee and stockholder of

633 views • 16 slides
OVERALL SURVIVAL IN KATE2 (NCT02924883): A PHASE 2 STUDY OF PD-L1 INHIBITOR ATEZOLIZUMAB +

OVERALL SURVIVAL IN KATE2 (NCT02924883): A PHASE 2 STUDY OF PD-L1 INHIBITOR ATEZOLIZUMAB +

OVERALL SURVIVAL IN KATE2 (NCT02924883): A PHASE 2 STUDY OF PD-L1 INHIBITOR ATEZOLIZUMAB + TRASTUZUMAB EMTANSINE (T-DM1) VS PLACEBO + T-DM1 IN PREVIOUSLY TREATED HER2-POSITIVE ADVANCED BREAST CANCER Leisha A. Emens , 1 Francisco Esteva, 2 Mark

747 views • 17 slides
MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF- B Inhibitor, in 4 to 7-Year Old Patients with

MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF- B Inhibitor, in 4 to 7-Year Old Patients with

MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF- B Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy Richard Finkel, MD 1, ; Krista Vandenborne, PT, PhD. 2 , H Lee Sweeney, PhD. 2 , Erika Finanger, MD 3 , Gihan Tennekoon,

610 views • 22 slides
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors Vivek Subbiah 1 , Mimi I Hu 1 , Justin F. Gainor 2 , Aaron Scott Mansfield 3 , Guzman Alonso 4 , Matthew H Taylor 5 , Viola Weijia Zhu 6 , Pilar

542 views • 15 slides
CTP-543, an Oral JAK Inhibitor, Achieves Primary Endpoint in Phase 2 Randomized,

CTP-543, an Oral JAK Inhibitor, Achieves Primary Endpoint in Phase 2 Randomized,

European Academy of Dermatology and Venereology Annual Congress October 12, 2019 CTP-543, an Oral JAK Inhibitor, Achieves Primary Endpoint in Phase 2 Randomized, Placebo-Controlled Dose-Ranging Trial in Patients with Moderate-to-Severe Alopecia

782 views • 20 slides
Cu Curr rrent t and Em Emerging Rol ole of of Immune Ch Checkpoi oint t Inhibitor ors s

Cu Curr rrent t and Em Emerging Rol ole of of Immune Ch Checkpoi oint t Inhibitor ors s

Cu Curr rrent t and Em Emerging Rol ole of of Immune Ch Checkpoi oint t Inhibitor ors s in th the Ma Management t of of mCR CRC Michael J Overman, MD Professor Department of Gastrointestinal Medical Oncology Division of Cancer

519 views • 21 slides
THE THERAPEUTIC POTENTIAL OF XANAMEM, A POTENT INHIBITOR OF THE 11 -HSD1 ENZYME Authors : T.

THE THERAPEUTIC POTENTIAL OF XANAMEM, A POTENT INHIBITOR OF THE 11 -HSD1 ENZYME Authors : T.

CHRONICALLY ELEVATED CORTISOL AND COGNITIVE IMPAIRMENT: THE THERAPEUTIC POTENTIAL OF XANAMEM, A POTENT INHIBITOR OF THE 11 -HSD1 ENZYME Authors : T. Miller 1 , C. Ritchie 2 , J.W. Ketelbey 1 ; 1 Australia, 2 United Kingdom Presented by Prof

739 views • 38 slides
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano,

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano,

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for the OSLER Investigators American College

226 views • 18 slides
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano,

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano,

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for the OSLER Investigators American College

505 views • 17 slides
Olutasidenib (FT-2102), an IDH1m Inhibitor as a Single Agent or in Combination With Azacitidine,

Olutasidenib (FT-2102), an IDH1m Inhibitor as a Single Agent or in Combination With Azacitidine,

Olutasidenib (FT-2102), an IDH1m Inhibitor as a Single Agent or in Combination With Azacitidine, Induces Deep Clinical Responses With Mutation Clearance in Patients With Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion

166 views • 14 slides
EOS in inhibitor pts Brussels, 27 June 2017 Luigi Solimeno Direttore UOC di Ortopedia e

EOS in inhibitor pts Brussels, 27 June 2017 Luigi Solimeno Direttore UOC di Ortopedia e

EOS in inhibitor pts Brussels, 27 June 2017 Luigi Solimeno Direttore UOC di Ortopedia e Traumatologia Servizio delle Malattie Rare IRCCS Ospedale Policlinico Fondazione C Granda - Milano 1 PWH today Adults (arthropathy) Kids on

626 views • 41 slides

More recommend